Platelet-activating factor and cardiac diseases: Therapeutic potential for PAF inhibitors

Journal of Lipid Mediators and Cell Signalling

Volumn 15, Issue 3, 1997, Pages 255-284

  Feuerstein, Giora ^a   Rabinovici, Reuven ^b   Leor, Jonathan ^c   Winkler, James D ^a   Vonhof, Stefan ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

Author keywords

Cardiac diseases; Platelet activating factor; Therapeutic potential

Indexed keywords

1 [2 [[5 (N OCTADECYLCARBAMOYLOXYMETHYL)TETRAHYDROFURFURYLOXY]HYDROXYPHOSPHINYLOXY]ETHYL]QUINOLINIUM; 2 O ETHYL 1 O HEXADECYL 3 O (7 THIAZOLIOHEPTYL)GLYCEROL MESYLATE; 2 [N (2 METHOXY 3 OCTADECYLCARBAMOYLOXYPROPOXYCARBONYL)ACETAMIDOMETHYL] 1 ETHYLPYRIDINIUM CHLORIDE; 2,5 BIS(3,4,5 TRIMETHOXYPHENYL)TETRAHYDROFURAN; 3 (3 PYRIDYL) 1H,3H PYRROLO[1,2 C]THIAZOLE 7 CARBOXAMIDE; 3 BROMO 5 [N PHENYL N [2 [[2 (1,2,3,4 TETRAHYDRO 2 ISOQUINOLYLCARBONYLOXY)ETHYL]CARBAMOYL]ETHYL]CARBAMOYL] 1 PROPYLPYRIDINIUM NITRATE; 6 (2 CHLOROPHENYL) 8 DIPROPYLCARBAMOYL 8,9 DIHYDRO 1 METHYL 4H,7H CYCLOPENTA[4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; 6 (2 CHLOROPHENYL) 9 [(3,4 DIMETHOXYPHENYL)THIOMETHYLTHIOCARBONYL] 4,7,8,10 TETRAHYDRO 1 METHYLPYRIDO[4',3':4,5]THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE; APAFANT; AZATHIOPRINE; BEPAFANT; BN 50726; CYCLOSPORIN A; CYTOKINE; FR 72112; GINKGOLIDE B; ICOSANOID; INDOMETACIN; KADSURENONE; LEUKOTRIENE; PHOSPHOLIPID; PREDNISOLONE; SRI 63675; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; THROMBOXANE A2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; [2 METHOXY 3 (N OCTADECYLCARBAMOYLOXY)PROPYL] (2 THIAZOLIOETHYL) PHOSPHATE;

ANIMAL MODEL; CHRONOTROPISM; CORONARY ARTERY CONSTRICTION; HEART ARRHYTHMIA; HEART DISEASE; HEART INFARCTION; HEART INJURY; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATORY CELL; INOTROPISM; MEDIATOR; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUDDEN DEATH;

EID: 18544405054     PISSN: 09297855     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-7855(96)00562-7     Document Type: Article

References (183)

1. Abete, P., Ferrara, N., Leosco, D. et al.(1992) Age-related effects of platelet activating factor (PAF) in the isolated perfused rat heart. J. Mol. Cell Cardiol. 24, 1399-1407.
2. Aehringhaus, U., Peakar, B.A., Wittenberg, H.R. and Wobling, R.H. (1983) Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis. Br. J. Pharmacol. 80, 73-80.
3. 4-like activity and on coronary flow in indomethacin-treated anaphylactic guinea-pig hearts. Arch. Pharmacol. 326, 368-374.
4. Allan, G. and Levi, R. (1980) The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N 1064. J. Pharmacol. Exp. Ther. 214, 45-49.
5. Allan, G. and Levi, R. (1981) Thromboxane and prostacyclin release during cardiac immediate hypersensitivity reactions in vitro. J. Pharmacol. Exp. Ther. 217, 157-161.
6. Alloatti, G., Montrucchio, G. and Camussi, G. (1994). Role of platelet-activating factor (PAF) in oxygen radical-induced cardiac dysfunction. J. Pharmacol. Exp. Ther. 269, 766-771.
7. Alloatti, G., Montrucchio, G., Mariano, F. et al. (1986) Effect of platelet-activting factor (PAF) on human cardiac muscle. Int. Arch. Allergy Appl. Immunol. 79, 108-112.
8. Alloatti, G., Montrucchio, G., Emanuelli, G. and Camussi, G. (1992). Platelet-activating factor (PAF) induces platelet neutrophil co-operation during myocardial reprofusion. J Mol. Cell Cardiol. 24, 163-171.
9. Alloatti, G., Montrucchio, G., Mariano, F., Tetta, C., Emanuelli, G.C. and Camussi, G. (1987) Protective effect of verapamil on the cardiac and circulatory alterations induced by platelet-activating factor. J. Cardiovasc. Pharmacol. 9, 181-186.
10. Anhut, H., Bernauer, W. and Peskar, B.A. (1978) Pharmacological modification of thromboxane and prostaglandin release in cardiac anaphylaxis. Prostaglandins 15, 889-900.
11. Annable, C.R., McManus, L.M., Carey, K.D. and Pinckard, R.N. (1985) Isolation of platelet-activating factor (PAF) from ischémic baboon myocardium. Fed. Proc. 44, 1271.
12. Arnould, T., Michiels, C. and Remacle, J. (1993) Increased PMN adherence on endothelial cells after hypoxia: involvement of PAF, CD18/CD11b, and ICAM-1. Am. J. Physiol. 264, C1102-1110.
13. Baker, R.R. and Chang, H. (1993). The potential for platelet-activating factor synthesis in brain: properties of cholinephosphotransferase and 1-alkyl-sn-glycero-3-phosphate acetyltransferase in microsomal fractions of immature rabbit cerebral cortex. Biochim. Biophys. Acta Lipids Lipid Metab. 1170, 157-164.
14. Baranes, J., Hallegouarch, A., LeHegarat, M. et al. (1986) The effects of PAF-acether on the cardiovascular system and their inhibition by a new highly specific PAF-acether receptor antagonist BN 52021. Pharmacol. Res. Commun. 18, 717-737.
15. Becker, K., Heinroth-Hoffmann, I., Giessler, C., Ponicke, K. and Brodde, O.E. (1995) PAF effects on eicosanoid release in neonetal rat cardiomyocytes. Prostaglandins Leukotrienes Essent. Fatty Acids 53, 197-200.
16. Bensard, D.D., Anderson, B.O., Banerjee, A. et al. (1992) Platelet activating factor alters receptor-coupled function in the isolated perfused rat heart. J. Surg. Res. 53, 312-325.
17. Benveniste, J., Henson, P.M. and Cochrane, C.G. (1972) Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils, and platelet-activating factor. J. Exp. Med. 136, 1356-1377.
18. Benveniste, J., Boullet, C., Brink, C. and Labat, C. (1983) The actions of PAF-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br. J. Pharmacol. 80, 81-83.
19. Benveniste, J. (1985) PAF-acether (platelet-activating factor). Adv. Prost. Thromb. Leukotriene Res. 13, 11.
20. Berti, F., Gall, G., Magni, F., Puglisi, L., Rosoni, G. and Villa, L. BN 52021, a specific PAF receptor antagonist, prevents antigen-induced mediator release and myocardial changes in guinea-pig perfused hearts. In: Braquet P. (Ed.). Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives, J.R. Prous Science, SA, 1988, pp. 399-410.
21. Berti, F., Gall, G., Magni, F., Rossoni, G. and Villa, G. The ginkgolide BN 52021 protects guinea-pig from lung and heart anaphylaxis. In: Braquet P. (Ed.). Ginkgolides - Chemistry, Biology, Pharmacology and Clinical Perspectives, J.R. Prous Science, SA, 1988 pp. 399-410.
22. Bessin, P., Bonnett, J., Apffel, D. et al. (1983) Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur. J. Pharmacol. 85, 403-413.
23. 2. J. Biol. Chem. 260, 6899-6906.
24. Black, S.C., Driscoll, E.M. and Lucchesi, B.R. (1992) Inhibition of platelet-activating factor fails to limit ischemia and reperfusion-induced myocardial damage. J. Cardiovasc. Pharmacol. 20, 997-1005.
25. Bradley, L.M., Golstein, R.E., Feuerstein, G.Z. and Czaja, J.F. (1989) Circulatory effects of PAF-acether in the newborn piglets. Am. J. Physiol. 256, H205-H212.
26. Braquet, P. and Rola-Plesczczynski, M. (1987) Platelet-activating factor and cellular immune response. Immunol. Today 8, 345.
27. Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.B. (1987) Perspectives in platelet-activating factor research. Pharmacol. Rev. 39, 97-145.
28. Braquet, P. (1985) BN 52021 and related compounds: a new series of highly specific PAF-acether receptor antagonists. Prostaglandins 30, 687.
29. Braquet, P., Paulbert-Braquet, M., Koltai, M., Bourgain, R., Bussolino, F. and Hosford, D. (1989) Is there a case for PAF antagonists in the treatment of ischemic states? TIPS 10, 23-30.
30. Bratton, D. and Henson, P.M. Cellular origin of PAF. In: P.J. Bames, C.P. Page and P.M. Henson (Eds.), Platelet-Activating Factor and Human Disease. Blackwell Scientific, Oxford, London (1989).
31. Bucoke, M., Weyrich, A.S. and Lefer, M. (1994). Isolated cardiac myocytes are sensitized by hypoxia-reoxygenation to neutrophil released mediators. Am. J. Physiol. 266, H128-H136.
32. Burghardt, C. and Janero, D.R. (1987) The anoxic rat-heart myocyte produces and releases platelet-activating (PAF) as a component of its ischemia-like pathology. J. Mol. Cell. Cardiol. 19, S69.
33. Burhop, K.E., Garcoa, J.G., Selig, W.M. et al. (1986) Platelet-activating factor increases lung vascular permeability to protein. J. Appl. Physiol. 61, 2210-2217.
34. Bussolino, F. and Camussi, G. (1980) Effect of prostacyclin on platelet-activating factor induced rabbit platelet aggregation. Prostaglandins 20, 781-791.
35. Camussi, G., Alloatti, G., Montrucchio, G., Meda, M. and Emanuelli, G. (1984) Effect of platelet-activating factor on guinea-pig papillary muscle. Experientia 40, 697-699.
36. Camussi, G., Niesen, N., Tetta, C., Saunders, R.N. and Milgrom, F. (1987) Release of platelet-activating factor from rabbit heart perfused in vitro by sera with transplantation alloantibodies. Transplantation 44, 113-118.
37. Casals-Stenzel, J., Muacevic, G. and Weber, K.-H. (1986) WEB 2086, a new and specific antagonist of platelet activating factor (PAF) in vitro and in vivo. Naunyn-Schmiedeberg Arch. Pharmacol. 334 (Suppl.) R44.
38. Cervoni, P., Herzlinger, H.E., Lai, L.M. and Tanikella, T.E. (1983) Aortic vascular and atrial response to (+y/-)-1-0-octadecyl-2-acetyl-glyceryl-3-phosphorylcholine. Br. J. Pharmacol. 79, 667-671.
39. Chakrabarty, S., Thomas, P. and Sheridan, D.J. (1989) Platelet activating factor antagonist benefits the heart during acute coronary artery occlusion. Circulation (Suppl.), 2-233.
40. Chakrabarty, S., Thomas, P. and Sheridan, D.J. (1991) Contribution of platelets and platelet-activating factor (PAF) to the arrhythmogenic, hemodynamic and necrotic effects of acute myocardial ischemia. Eur. Heart J. 12, 583-589.
41. Chao, W. and Olson, M.S. (1993). Platelet-activating factor: receptors and signal transduction. Biochem. J. 292, 617-629.
42. Chopra, U., Jingh, M., Gupta, S. and Ganguly, N.Y. (1993). Involvement of oxygen free radicals in the action of BN 52021 (PAF antagonist) to limit myocardial infarct size. Methods Find. Ex. Clin. Pharmacol. 15, 437-445.
43. 2+-antagonists verapamil and diltiazem and by trifluoperazine. Thromb. Res. 31, 565-576.
44. Colard, O., Bidault, J., Breton, M. and Ninio, E. (1993). Biosynthesis of platelet-activating factor in cultured mast cells - Involvement of the CoA-independent transacylase demonstrated by analysis of the molecular species of platelet-activating factor. Eur. J. Biochem. 216, 835-840.
45. Drawford, M.H., Grover, F.L., Kolb, W.P. et al. (1988). Complement and neutrophil activation in the pathogenesis of ischemic myocardial injury. Circulation 78, 1449-1458.
46. Engel, B. and Letts, L. (1985) Cardiovascular and pulmonary effects of platelet activating factor (PAF, PAF-acether) in the anesthetized pig. Pharmacologist 27, 576.
47. 2+). Biol. Trace Elem. Res. 50, 43-55.
48. 4 immunoreactivity in the intact domestic pig heart. Adv. in Prostaglandin, Thromb. Leukotrienes. Res. 13, 19-21.
49. Ezra, D., Laurindo, F.R.M., Czaja, J.F., Snyder, F., Goldstein, R.E. and Feuerstein, G. (1987) Cardiac and coronary consequences of intracoronary platelet activating factor infusion in the domestic pig. Prostaglandin 34, 41-57.
50. Feuerstein, G.Z., Boyod, L., Ezra, D. and Goldstein, R. (1984) Effect of platelet activating factor on coronary circulation of the domestic pig. J. Am. Physiol. 246, H466-H471.
51. Feuerstein, G.Z., Ezra, D., Ramwell, P., Letts, G. and Goldstein, R. Platelet activating factor as a modulator of cardiac and coronary function. In: Bailey J. (Ed.). Prostaglandins, Leukotrienes and Lipoxins. Plenum, New York, 1985, pp. 301-310.
52. Feuerstein, G.Z., Luz, W., Ezra, D., Hayes, E., Snyder, F. and Faden, A. (1985) Thyrotropin releasing hormone blocks the hypotensive effect of platelet activating factor in the unanesthetized guinea pig. J. Cardiovasc. Pharmacol. 7, 335-340.
53. Feuerstein, G.Z. and Goldstein, R.E. Effect of PAF on the cardiovascular system. In: Snyder, F. (Ed.). Platelet Activating Factor and Related Lipid Mediators. Plenum, New York. 1987, pp. 403-424.
54. Feuerstein, G.Z. and Siren, A.-L. (1988) Platelet activating factor and shock. Prog. Biochem. Pharmacol. 22, 181-190.
55. Flores, N.A., Goulielmos, N.V., Seghatchian, M.J. and Sheridan, D.J. (1994) Myocardial ischemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. Cardiovasc. Res. 28, 1662-1671.
56. Foegh, M.L., Khirabadi, B.S., Rowles, J., Braquet, P. and Ramwell, P.W. (1986a) Prolongation of rat cardiac allograft survival with BN 52021, a specific antagonist of platelet-activating factor. Transplantation 42, 86-88.
57. Foegh, M.L., Khirabadi, B.S., Rowles, R.J., Braquet, P. and Ramwell, P.W. (1986b) The causal role of PAF and leukotrienes in acute cardiac allograft rejection in rats. Pharmacol. Res. Comm. 18 (Suppl.) 127-132.
58. Fonteh, A.N., Winkler, J.D., Torphy, T.J., Heravi, J., Undem, B.J. and Chilton, F.H. (1993). Influence of isoproterenol and phosphodiesterase inhibitors on platelet-activating factor biosynthesis in the human neutrophil. J. Immunol. 151, 339-350.
59. Gerard, N.P. and Gerard, C. (1994). Receptor-dependent internalization of platelet-activating factor. J. Immnunol. 152, 793-800.
60. Goldstein, B.M., Gabel, R.A. and Huggins, F.J. (1981) Effect of platelet-activating factor (PAF) on blood flow distribution in the spontaneously hypertensive rat. Life Sci. 35, 1373-1378.
61. Goldstein, R.E., Ezra, D., Laurindo, F.R.M. and Feuerstein, G.Z. (1986) Coronary and pulmonary vascular effects of leukotrienes and PAF-acether. Pharmacol. Res. Commun. 18, 151-162.
62. Guillon, J.M., Rochette, L. and Baranes, J. Effects of Ginkgo Biloba extract on two models of experimental myocardial ischemia. In: Funfgeld E.W. (Ed.). Rokan (Ginkgo Biloba), Recent Results in Pharmacology and Clinic. Springer-Verlag, Berlin, 1988, pp. 153-161.
63. Gupta, J.B., Presad, M., Voltra, J. and Presad, U. (1988) Platelet activating factor induced changes in cardiovascular function and oxyradical status of myocardium in presence of the PAF antagonist CV-6209. Angiology 45, 25-36.
64. Hanahan, D. (1986) Platelet-activating factor: a biologically phosphoglyceride. Ann. Rev. Biochem. 55, 483-509.
65. Handley, D.A., Van Valen, R.G., Winslow, C.M., Tomesch, J.C. and Saunders, R.N. (1987) In vitro and in vivo pharmacologic profiles of the PAF receptor antagonist SRI 63-675. Thromb. Haemost. 57, 187-190.
66. Hayashi, M., Imai, Y., Naraba, H., Tomoda, H., Omura, S. and Oh-ishi, S. (1992). Enhanced production of platelet-activating factor in stimulated rat leukocytes pretreated with triacsin C, a novel acyl-CoA synthetase inhibitor. Biochem. Biophys. Res. Commun. 188, 1280-1285.
67. Heller, R., Bussolino, F., Ghigo, D. et al. (1991a). Stimulation of platelet-activating factor synthesis in human endothelial cells by activation of the de novo pathway. Phorbol 12-myristate 13-acetate activates 1-alkyl-2-lyso-sn-glycero-3-phosphate:acetyl-CoA acetyltransferase and dithiothreitol-insensitive 1-alkyl-2-acetyl-sn-glycerol:CDP-choline cholinephosphotransferase. J. Biol. Chem. 266, 21358-21361.
68. Heller, R., Bussolino, F., Ghigo, D. et al. (1991b). Protein kinase C and cyclic AMP modulate thrombin-induced platelet-activating factor synthesis in human endothelial cells. Biochim. Biophys. Acta Mol. Cell Res. 1093, 55-64.
69. Herbert, J.M., Fraisse, L., Bailey, A. et al. (1993). Biochemical and pharmacological properites of SR 27388, a dual antioxidant and PAF receptor antagonist. J. Lipid Mediat. 8, 31-51.
70. Herrick-Davis, K., Camussi, G., Bussolino, F. and Baglioni, C. (1991). Modulation of neurite outgrowth in neuroblastoma cells by protein kinase C and platelet-activating factor. J. Biol. Chem. 266, 18620-18625.
71. Ho, S., Camussi, G., Tetta, C., Milgrow, F. and Andres, G. (1984) Hyperacute allograft rejection in the rabbit. Lab. Invest. 51, 148.
72. Hu, W., McNicholl, I.K., Choy, P.C. and Man, R.Y. (1993) Partial agonist effect of the platelet-activating factor receptor antagonists, WEB 2086 and WEB 2170, in the rat perfused heart. Br. J. Pharmacol. 110, 645-650.
73. Ihara, Y., Frenkel, R.A. and Johnston, J.M. (1993). Hormonal regulation of platelet-activating factor-acetyltransferase activity in rat tissues. Arch. Biochem. Biophys. 304, 503-507.
74. Jackson, C.V., Schumacher, W.A., Kunkel, S.L., Driscoll, E.M. and Lucchesi, B.R. (1986) Platelet-activating factor and the release of platelet-derived coronary artery vasodilator substance in the canine. Circ. Res. 58, 218-229.
75. Kamitani, T., Katamoto, M., Tasumi, M. et al. (1984). Mechanisms of the hypotensive effect of 1-0-octadecyl-2-0-acetyl-glyceryl-3-ohosphorylcholine. Eur. J. Pharmacol. 98, 357-366.
76. Katoh, S., Toyama, J., Kodama, I., Koike, A. and Abe, T. (1993) Role of platelet activating factor in ischaemia-reperfusion injury of isolated rabbit hearts: protective effect of a specific platelet activating factor antagonist, TCV-309. Cardiovasc. Res. 27, 1430-1434.
77. Kelefiotis, D., Lanara, E., Vakirtzi-Lemonias, C. et al. (1988) Study of digoxin as inhibitor of the in vivo effects of acetyl glyceryl ether phosphorylcholine (AGEPC) in mice. Life Sci. 42, 623-633.
78. Kenzora, J.L., Perez, J.E., Bergmann, S.R. and Lange, L.G. (1984) Effects of acetyl glyceryl ether phosphorylcholine (platelet-activating factor) on ventricular preload, afterload and contractility in dogs. J. Clin. Invest. 74, 1193-1203.
79. Khirabadi, B.S., Foegh, M.L., Goldstein, H.A. and Ramwell, P.W. (1987) The effect of prednisolone, thromboxane and platelet-activating factor receptor antagonism on lymphocyte and platelet migration in experimental cardiac transplantation. Transplantation 43, 626-630.
80. Kim, Y.D., Dauchek, R.M., Heim, K.F., Lees, D.E. and Myers, A.U. (1993). Constriction of canine coronary arteries by platelet activating factor after brief ischemia. Prostaglandins 46, 269-276.
81. Koltai, M., Lepran, I., Szekeres, L., Viossat, I., Chabrier, E. and Braquet, P. (1986) Effect on BN 52021, a specific PAF-acether antagonist, on cardiac anaphylaxis in Langendorff hearts isolated from passively sensitized guinea-pigs. Eur. J. Pharmacol. 130, 133-136.
82. Koltai, M., Tosaki, A., Braquet, P. and Szekeres, L. PAF-acether in cardiac anaphylaxis: effect of BN 52021, a specific PAF-acether receptor antagonist on passively sensitized, isolated working guinea-pig heart. In: Braquet P. (Ed.). The Role of Platelet-Activating Factor in Immune Disorders. New Trends in Lipids Mediators Research, Vol. 2 ,Karger, Basel, 1988, pp. 145-152.
83. Koltai, M., Tasaki, A., Hosford, D. and Braquet, P. (1989a) BN 52021, a PAF receptor antagonist, protects isolated working rat hearts against arrhythmias induced by ischemia but not reperfusion. Eur. J. Pharmacol. 164, 293-302.
84. Koltai, M., Tosaki, A., Guillon, J.M., Hosford, D. and Braquet, P. (1989b) PAF antagonists as potential therapeutic agents in cardiac anaphylaxis and myocardial ischemia. Cardiovasc. Drug Reviews 7. Raven Press, New York, pp. 177-189.
85. Kubes, P., Ibbotson, G., Russell, J., Wallace, J.L. and Granger, D.N. (1990). Role of platelet-activating factor in ischemia/reperfusion-induced leukocyte adherence. Am. J. Physiol. 259, G300-G305.
86. 2 analog. Clin. Res. 33, 203.
87. Lee, T., Malone, B., Woodard, D. and Snyder, F. (1989). Renal necrosis and the involvement of a single enzyme of the de novo pathway for the biosynthesis of platelet-activating factor in the rat kidney inner medulla. Biochem. Biophys. Res. Commun. 163, 1002-1005.
88. Leong, L., Sturm, M. and Taylor, R. (1991) The lyso-precursor of platelet-activating factor (lyso-PAF) in ischemic myocardium. J. Lipid Med. 4, 277-288.
89. Leong, L.L., Stephens, C.J., Sturm, M.J. and Taylor, R.R. (1992) Effect of WEB 2086 on myocardial infarct size and regional blood flow in the dog. Cardiovasc. Res. 26, 126-132.
90. Lepran, I. and Lefer, A.M. (1985) Ischemia aggravating effects of platelet-activating factor in acute myocardial ischemia. Basic Res. Cardiol. 80, 135-141.
91. Levi, R., Burke, J.A., Guo, Z.G. et al. (1984) Acetyl glyceryl ether phosphorylcholine (AGEPC), a putative mediator of cardiac anaphylaxis in the guinea pig. Circ. Res. 54, 117-124.
92. Levy, J.V. (1983) Calmodulin antagonist inhibits aggregation of human, guinea pig, and rabbit platelets induced with platelet-activating factor. FEBS Lett. 154, 262-264.
93. Leyravaud, S., Bossant, M.-J., Joly, F., Bessou, G., Benveniste, J. and Ninio, E. (1989). Biosynthesis of PAF-anether. Phorbol myristate acetate-induced PAF-ancether biosynthesis and acetyltransferase activation in human neotrophils. J. Immunol. 143, 245-249.
94. Lotner, G.Z., Lynch, J.M., Betz, S.J. and Henson, P.M. (1980) Human neutrophil-derived platelet activating factor. J. Immunol. 124, 676-684.
95. Ma, X.-L., Weyrich, A.S., Krantz, S. and Lefer, A.M. (1991) Mechanisms of the cardioprotective actions of WEB-2170, a bepafant, a platelet-activating factor antagonist, in myocardial ischemia and reperfusion. J. Pharmacol. Exp. Ther. 260, 1229-1236.
96. Maruyama, M., Farber, N.E., Vercellotti, G.M., Jacob, H.S. and Gross, G.J. (1989a) Inhibition of platelet-activating factor does not alter myocardial stunning. J. Mol. Cell Cardiol. 21 (Suppl. 2) S115.
97. Maruyama, M., Vercellotti, G.M., Jacob, H.S. and Gross, G.J. (1989b) Platelet activating factor as a mediator of myocardial infarction. Circulation 2 (Suppl.) 233.
98. Maruyama, M., Vercellotti, G.M., Jacob, G., Gross, G. and Christensen, C. (1989c) Inhibition of platelet-activating factor reduces myocardial infarct size. J. Mol. Cell Cardiol. 21 (Suppl. II) S 114.
99. Massey, C.V., Kohout, T.A., Gaa, ST., Lederer, W.J. and Rogers, T.B. (1991) Molecular and cellular actions of platelet-activating factor in rat heart cells. J. Clin. Invest. 88, 2106-2116.
100. McIntyre, S.W. and Shaw, A.M. (1984) Phospholipid-induced human platelet activation: effects of calcium channel blockers and calcium chelators. Thromb. Res. 31, 823-844.
101. 4 by human neutrophils. J. Biol. Chem. 262, 15370-15376.
102. Mentz, P., Mentz, G., Giessler, C. and Mest, H.J. (1992) Interactions of prostanoids with the platelet activating factors. Prostaglandins Leukotrienes Essent. Fatty Acids. 47, 13-16.
103. Metha, J., Wargovich, T. and Nichols, W. (1986) Biphasic effects of platelet-activating factor on coronary blood flow in anesthetized dog. Prostglandins Leukotrienes Med. 21, 87-95.
104. Mickelson, J.K., Simpson, P.J. and Lucchesi, B.R. (1988) Myocardial dysfunction and coronary vasoconstriction induced by platelet-activating factor in the post-infarcted rabbit isolated heart. J. Mol. Cell Cardiol. 20, 547-561.
105. Montrucchio, G., Camussi, G., Tetta, C. et al. (1986) Intravascular release of platelet-activating factor during atrial pacing. Lancet 2, 293.
106. Montrucchio, G., Ausati, G., Tetta, C. et al. (1989) Release of platelet-activating factor from ischemic rabbit heart. Am. J. Physiol. 256, H1236-H1246.
107. Montrucchio, G., Alloatti, G., Mariano, F. et al. (1990) Role of platelet-activating factor in the reperfusion injury of rabbit ischemic heart. Am. J. Pathol. 137, 71-83.
108. Montrucchio, G., Alloatti, G., Mariano, F. et al. (1993) Role of platelet-activating factor in polymorphonuclear neutrophil recruitment in reperfused ischemic rabbit heart. Am. J. Pathol. 142, 471-480.
109. Müller, S. and Nigam, S. (1992). Arachidonic acid release and platelet-activating factor formation by staurosporine in human neutrophils challenged with n-formyl peptide. Eur. J. Pharmacol. 218, 251-258.
110. Myer, A.K. and Bader, T.J. (1987) Role of adrenal steroids in the recovery from platelet-activating factor challenge. Circ. Shock 23, 143-150.
111. Nakaya, H. and Tohse, N. (1986) Electrophysiological effects of acetyl-glyceryl-ether-phosphorylcholine on cardiac tissues in comparison with lysophosphatidylcholine and long chain acyl carnitine. Br. J. Pharm. 89, 749-757.
112. Nakaya, R. and Kunihiko, S. (1989) Presence of 1-0-alk-1-enyl-20-acetyl glycerophosphocholine (vinil form of PAF) in perfused rat and guinea pig hearts. J. Biochem. 105, 494-496.
113. Naraba, H., Imai, Y., Hayashi, M. and Oh-ishi, S. (1993). Enhanced production of platelet-activating factor in stimulated rat leukocytes caused by the blockade of lysophospholipid acylation. Jpn. J. Pharmacol. 61, 109-113.
114. Nies, A.S., Tunney, A., Barden, A., Sturm, M. and Vandongen, R. (1991). Release of platelet activating factor by the isolated kidney is not linked to the production of prostaglandins. J. Pharmacol. Exp. Ther. 259, 590-594.
115. Nieto, M.L., Venable, M.E., Bauldry, S.A. et al. (1991). Evidence that hydrolysis of ethanolamine plasmalogens triggers synthesis of platelet-activating factor via a transacylase reaction. J. Biol. Chem. 266, 18699-18706.
116. O'Flaherty, J.T. and Ramwell, P.W. (1990). Platelet-activating factor antagonists: new developments for clinical application. In: Advances in Applied Biotechnology, Series 9, Gulph, TX, pp. 12-30, pp. 47-82.
117. O'Flaherty, J.T., Tessner, T., Greene, D., Redman, J.R. and Wykle, R.L. (1994). Comparison of 1-0-alkyl-, 1-0-alkyl-1′-enyl-, and 1-0-acyl-2-acetyl-sn-glycero-3-phosphoethanolamines and -3-phosphocholines as agonists of the platelet-activating factor family. Biochim. Biophys. Acta 1210, 209-216.
118. O'Neill, C. (1992). Embryo-derived platelet activating factor. Reprod. Fertil. Dev. 4, 283-288.
119. Otsuka, A., Masugi, F., Ogihara, T. et al. (1985) Hypotensive mechanism of acetyl glyceryl ether phosphorylcholine (AGEPC) in dogs: effects of hemodynamics and humoral factors. Prostaglandin Leukotrienes Med. 19, 25-35.
120. Pinckard, R.N., Jackson, E.M., Hoppens, C. et al. (1984). Molecular heterogenity of platelet-activating factor produced by stimulated human polymorphonuclear leukocytes. Biochem. Biophy. Res. Commun. 122, 325-332.
121. 4. Br. J. Pharmacol. 88, 595-605.
122. Piper, P.I. and Stewart, A.G. (1986b) Evidence of a role for platelet-activating factor in antigen-induced coronary vasoconstriction in guinea-pig perfused hearts. Br. J. Pharmacol. 88, 238P.
123. Piper, P.J. and Stewart, A.G. (1987) Antagonism of vasoconstriction induced by platelet-activating factor in guinea-pig perfused hearts by selective platelet-activating factor antagonists, Br. J. Pharmacol. 90, 771-783.
124. Prescott, S.M., Zimmerman, G.A. and McIntyre, T.M (1990). Platelet-activating factor. J. Biol. Chem. 265, 17381-17384.
125. Rabinovici, R., Yue, T-L., Farhat, M. et al. (1990) Platelet activating factor (PAF) and tumor necrosis factor-α (TNFα) interactions in endotoxemic shock: studies with BN 50739, a novel PAF antagonist. J. Pharmacol. Exp. Ther. 255, 256-263.
126. Raschke, P. and Becker, B.F. (1995) Adenosine and PAF dependent mechanisms lead to myocardial reperfusion injury by neutrophils after brief ischemia. Cardiovasc. Res. 29, 569-576.
127. Riedel, A. and Mest, H.J. (1987) The effect of PAF (platelet-activating factor) on experimental cardiac arrhythmias and its inhibition by substances influencing arachidonic acid metabolises. Adv. Prostaglandin Leukotrienes Med. 28, 103-109.
128. Robertson, D.A., Genovese, A. and Levi, R. (1987) Negative inotropic effect on platelet-activating factor on human myocardium: a pharmacological study. J. Pharmacol. Exp. Ther. 243, 834-839.
129. Robertson, D.A., Wang, D.Y., Lee, C.O.K. and Levi, R. (1988) Negative inotropic effect of platelet-activating factor: assocation with a decrease in intracellular sodium activity. J. Pharmacol. Exp. Ther. 245, 124-128.
130. 2+-dependent route of priming in the production of lipid mediators by human polymorphonuclear leukocytes. J. Biol. Chem. 268, 24751-24757.
131. Ryan, J.P., O'Neill, C., Ammit, A.J. and Roberts, C.G. (1992). Metabolic and developmental responses of preimplantation embryos to platelet activating factor (PAF). Reprod. Fertil. Dev. 4, 387-398.
132. Saeki, S., Masugi, F., Ogihara, T. et al. (1985) Effects of 1-alkyl-2-acetyl-sn-glycerol-3-phosphocholine (platelet-activating factor) on cardiac function in perfused guinea-pig heart. Life Sci. 37, 325-329.
133. Sanchez-Crespo, M., Alonso, F., Inarrea, P., Alaverz, V. and Edigo, J. (1982) Vascular actions of synthetic PAF acether (a synthetic platelet-activating factor) in the rat, evidence for a platelet independent mechanism. Immunopharmacology 4, 173-185.
134. Sawa, Y., Schaper, J., Roth, M. et al. (1994) Platelet-activating factor plays an important role in reperfusion injury in myocardium: efficacy platelet-activating factor receptor antagonist (CV-3988) as compared with leukocyte-depleted reperfusion. J. Thorac. Cardiovasc. Surg. 108, 953-959.
135. Schoonderwoerd, K. and Stam, H. (1992) Lipid metabolism of myocardial cells. Mol. Cell. Biochem. 116, 171-179.
136. Schroeder, E., Van Mechelan, H., Maldague, P. et al. (1989) Increased coronary vascular resistance in the stunned myocardium: role of the platelet-activating factor. Circ. Suppl. II, 77.
137. Shigenobu, K., Mori, T., Kamata, K. and Kasuya, Y. (1988) Platelet-activating factor: lack of direct action on guinea pig myocardium and possible transmitter release from cardiac sympathetic nerve endings at high concentrations. Can. J. Physiol. Pharmacol. 67, 669-674.
138. Shimizu, T., Honda, Z., Nakamura, M., Bito, H. and Izumi, T. (1992). Platelet-activating factor receptor and signal transduction. Biochem. Pharmacol. 44, 1001-1008.
139. Siren, A.-L, and Feuerstein, G.Z. (1989) Effect of platelet-activating factor and its antagonist BN 52021 on cardiac function and regional blood flow in the conscious rat. Am. J. Physiol. 257, H25-H32.
140. Smiley, P.L., Stremler, K.E., Prescott, S.M., Zimmerman, G.A. and McIntyre, T.M. (1991). Oxidatively fragmented phosphatidylcholines activate human neutrophils through the receptor for platelet-activating factor. J. Biol. Chem. 266, 11104-11110.
141. Snyder, F. Enzymatic pathways for platelet-activating factor, related alkyl glycerolipids and their precursors. In: Snyder, F. (Ed.). Platelet-Activating Factor and Related Lipid Mediators. Plenum, New York, 1987.
142. Snyder, F. (1990). Platelet-activating factor and related acetylated lipids as potent biologically active cellular mediators. Am. J. Physiol. Cell Physiol. 259, C697-C708.
143. Snyder, F., Lee, T.-C. and Blank, M.L. (1992). The role of transacylases in the metabolism of arachidonate and platelet-activating factor. Prog. Lipid Res. 31, 65-86.
144. Soloviev, A.E. and Braquet, P. (1989) The role of PAF-acether in the mechanism of isolated coronary artery spasm under hypoxia and its inhibition by BN 52021. In: Braquet P. (Ed.), Ginkgolides -Chemistry, Biology, Pharmacology and Clinical Perspectives. Vol. 2, J.R. Prous Science, S.A., 1990.
145. Stahl, G.L. and Lefer, A.M. (1987a) Heterogeneity of vascular smooth muscle responsiveness to lipid vasoactive mediators. Blood Vessels 24, 24-30.
146. Stahl, G.L., Lefer, D.J. and Lefer, A.M. (1987b) Mechanism of platelet-activating factor induced cardiac depression in the isolated perfused rat heart. Circ. Shock 23, 165-167.
147. Stahl, G.L., Lefer, D.J. and Lefer, A.M. (1987c) PAF-acether induced cardiac dysfunction in the isolated perfused guinea-pig heart. Naunyn-Schmiedeberg's Arch. Pharmacol. 336, 459-463.
148. Stahl, G.L., Terashita, Z.I. and Lefer, A.M. (1988) Role of platelet-activating factor (PAF) in the propagation of myocardial ischemic damage in the rat. J. Pharmacol. Exp. Ther. 24, 898-904.
149. Stewart, A.G. and Piper, P.J. (1986) Platelet-activating antagonists inhibit antigen-induced coronary vasoconstriction in guinea-pig hearts. Sixth Conf. Prostaglandins and Related Compounds, Florence, Italy, pp. 311 (Abst.).
150. Stewart, A.G. and Piper, P.J. Platelet-activating factor and the cardiovascular system: involvement in cardiac anaphylaxis. In: Braquet, P., Mangold, H.K., Vargaftig, B.B., (Eds.). Progress in Biochemical Pharmacology, Vol. 22, Karger, Basel, 1988, pp. 132-140.
151. Sturk, A., Schaap, M.C.L., Prins, A., Wouter ten Cate, J. and Van den Bosch, H. (1989). synthesis of platelet-activating factor by human blood platelets and leucocytes, evidence against selective utilization of cellular ether-linked phospholipids. Biochim. Biophys. Acta 993, 148-156.
152. Sugimoto, T., Tsuchimochi, H., McGregor, C.G., Mutoh, H., Shimizu, T. and Vurachi, Y. (1992). Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart. Biochem. Biophys. Res. Comm. 189, 617-624.
153. Sybertz, E.J., Watkins, R.W., Baum, T., Pula, K. and Rivelli, M. (1985) Cardiac, coronary and peripheral vascular effects on acetyl glyceryl ether phosphorylcholine in the anesthetized dog. J. Pharmacol. Exp. Ther. 232, 156-162.
154. Tamargo, J., Tejerina, T., Delado, C. and Barrigon, S. (1985) Electrophysiological effects of platelet-activating factor (PAF-acether) in guinea-pig papillary muscles. Eur. J. Pharmacol. 109, 219-227.
155. Tanaka, T., Iimori, M., Tsukatani, H. and Tokumura, A. (1994). Platelet-aggregating effects of platelet-activating factor-like phospholipids formed by oxidation of phosphatidylcholines containing an sn-2-polyunsaturated fatty acyl group. Biochim. Biophys. Acta 1210, 202-208.
156. Tanniere, M. and Rochette, L. (1987) Direct effects of platelet-activating factor (PAF) on cardiac function in isolated guinea pig heart. Drug Dev. Res. 11, 177-186.
157. 2) against constrictor mediators in isolated rat heart and lung. Biochem. Pharmacol. 37, 2659-2665.
158. Triggiani, M. and Chilton, F.H. (1992). Metabolism of platelet-activating factor in the guinea-pig heart. J. Mol. Cell. Cardiol. 24, 1101-1111.
159. Triggiani, M., Fonteh, A.N. and Chilton, F.H. (1992a). Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell. Biochem. J. 286, 497-503.
160. Triggiani, M., Goldman, D.W. and Chilton, F.H. (1991a). Biological effects of 1-acyl-2-acetyi-sn-glycero-3-phosphocholine in the human neutrophil. Biochim. Biophys. Acta Lipids Lipid Metab. 1084, 41-47.
161. Triggiani, M., Schleimer, R.P., Warner, J.A. and Chilton, F.H. (1991b). Differential synthesis of 1-acyl-2-acetyl-sn-glycero-3-phosphocholine and platelet-activating factor by human inflammatory cells. J. Immunol. 147, 660-666.
162. Triggiani, M., Schleimer, R.P., Tomioka, K., Hubbard, W.C. and Chilton, F.H. (1992b). Characterization of platelet-activating factor synthesized by normal and granulocyte-macrophage colony-stimulating factor-primed human eosinophils. Immunology 77, 500-504.
163. Tselepis, A.D., Evangelou, A., Tsoukatos, D., Demopoulos, C.A. and Kapoulas, V.M. (1987) Electrocardiographic alterations induced by AGEPC in Wistar rats in relation to its hypotensive and hematologic effects. Biochem. Physiol. 87C, 41-46.
164. Uemura, Y., Lee, T. and Snyder, F. (1991). A coenzyme A-independent transacylase is linked to the formation of platelet-activating factor (PAF) by generating the lyso-PAF intermediate in the remodeling pathway. J. Biol. Chem. 266, 8268-8272.
165. Vargaftig, BB., Fouque, F. and Lefort, J.J. (1984) Platelet aggregation and PAF-acether, pharmacological interferences. J. Pharmacol. (Paris) 15, 69-84.
166. Venable, M.E., Nieto, M.L., Schmitt, J.D. and Wykle, R.L. (1991). Conversion of 1-0-[3H]Alkyl-2-arachidonoyl-sn-glycero-3-phosphocholine to lyso-platelet-activating factor by the CoA-independent transacylase in membrane fraction of human neutrophils. J. Biol. Chem. 266, 18691-18698.
167. Venable, M.E., Olson, S.C., Nieto, M.L. and Wykle, R.L. (1993a). Enzymatic studies of lyso platelet-activating factor acylation in human neutrophils and changes upon stimulation. J. Biol. Chem. 268. 7965-7975.
168. Venable, M.E., Zimmerman, G.A., McIntyre, T.M. and Prescott, S.M. (1993b). Platelet-activating factor: A phospholipid autacoid with diverse actions. J. Lipid Res. 34, 691-702.
169. Viossat, I., Chabrier, P.E., Chapelat, M. and Braquet, P. (1987) The coronary, inotropic, chronotropic and arrhythmogenic effects of PAF-acether on isolated guinea-pig heart and their selective inhibition by BN 52021. In: Paubert-Braquet, M. (Ed.). Lipid Mediators in the Immunology of Shock. Plenum, New York, pp. 513-517.
170. Vleeming, W., Wemer, J. and Porsius, A.J. (1992) Modulation of antigen-and ischemia-induced effects by the platelet-activating antagonist WEB-2086 in isolated sensitized rat hearts. J. Cardiovasc. Pharmacol. 20, 790-799.
171. Voelkel, N.F., Worthen, S., Reeves, J.T., Henson, P.M. and Murphy, R.C. (1982) Nonimmunological production of leukotrienes induced platelet-activating factor. Science 218, 286-288.
172. Wainwright, C.L., Parratt, J.R. and Bigaud, M. (1988) The effects of PAF antagonists on ischemic and reperfusion arrhythmias and ischemia-induced platelet aggregation. Biomed. Biochem. Acta 47, S224-S227.
173. Wahler, G.M., Coyle, D.E. and Sperelakis, N. (1990) Effects of platelet-activating factor on single potassium channel currents in guinea pig ventricular myocytes. Mol. Cell. Biochem. 93, 69-76.
174. Whatley, R.E., Clay, K.L., Chilton, F.H. et al. (1992). Relative amounts of 1-0-alkyl-and 1-acyl-2acetyl-sn-glycero-3-phosphocholine in stimulated endothelial cells. Prostaglandins 43, 21-29.
175. Whatley, R.E., Nelson, P., Zimmerman, G.A. et al. (1989). The regulation of platelet-activating factor production in endothelial cells. The role of calcium and protein kinase C. J. Biol. Chem. 264, 6325-6333.
176. Wheelan, P. and Clay, K.L. (1992). Albumin and fatty acid effects on the stimulated production of 1-0-hexadecyl-2-acetyl-sn-glycero-3-phosphocholine (PAF) by human polymorphonuclear leukocytes. Biochim. Biophys. Acta Lipids Lipid Metab. 1127, 284-292.
177. Winkler, J.D. and Chilton, F.H. (1993a). The role of CoA-independent transacylases in the production of platelet-activating factor and the metabolism of arachidonate. Drug News Perspec. 6, 133-138.
178. Winkler, J.D., Fonteh, A.N., Sung, C. -M. et al. (1995). Effects of CoA-independent transacylase inhibitors on the production of lipid inflammatory mediators. J. Pharmacol. Exp. Ther. 274, 1338-1347.
179. Winkler, J.D., Sung, C-M., Hubbard, W.C. and Chilton, F.H. (1992). Evidence for different mechanisms involved in the formation of lyso platelet-activating factor and the calcium-dependent release of arachidonic acid from human neutrophils. Biochem. Pharmacol. 44, 2055-2066.
180. 2 activity in the human neutrophil. Biochem. J. 291, 825-831.
181. Wykle, R.L. Interrelationships in the metabolism of platelet-activating factor and arachidonate in neutrophils. In: Snyder, F. (Ed.). Platelet-activating Factor and Related Lipid Mediators. Plenum, New York, 1987, pp. 273-282.
182. Wykle, R.L., Malone, B. and Snyder, F. (1980). Enzymatic synthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine, a hypotensive and platelet-aggregating lipid. J. Biol. Chem. 255, 10256-10260.
183. Yue, T.-L., Farhat, M., Rabinovici, R., Perera, P.Y., Vogel, S.N. and Feuerstein, G. (1990) Protective effect of BN 50739, a new PAF antagonist, on endotoxin treated rabbits. J. Pharmacol. Exp. Ther. 254, 976-981.